Stock Events

Stock Events

Exicure 

€5.02
0
+€3.03+152.9% Thursday 13:24

Statistics

Day High
6.26
Day Low
5.02
52W High
6.26
52W Low
5.02
Volume
14,184
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q4 2022
Next
-0.88
5.95
12.79
19.62
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2H0.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.72B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, directly competing with Exicure's spherical nucleic acid (SNA) technology.
Ionis Pharmaceuticals
IONS
Mkt Cap12.42B
Ionis Pharmaceuticals specializes in antisense technology, which is a form of RNA-targeted therapy competing with Exicure's approach.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap9.12B
Arrowhead Pharmaceuticals develops drugs based on RNA interference, a similar field to Exicure's, making them direct competitors.
Moderna
MRNA
Mkt Cap20.21B
Moderna is known for mRNA technology, which, while different, competes in the broader space of nucleic acid therapies where Exicure operates.
BioNTech
BNTX
Mkt Cap24.15B
BioNTech SE, although famous for its mRNA COVID-19 vaccine, works on nucleic acid technologies that compete with Exicure's SNA platform.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics is focused on gene editing, a different but competing approach to treating diseases at the genetic level compared to Exicure.
Editas Medicine
EDIT
Mkt Cap287.74M
Editas Medicine operates in the gene editing space with CRISPR technology, offering a competing approach to Exicure's genetic intervention strategies.
Intellia Therapeutics
NTLA
Mkt Cap1.59B
Intellia Therapeutics is another key player in CRISPR-based gene editing, competing in the broader market of genetic therapies against Exicure.
Sarepta Therapeutics
SRPT
Mkt Cap2.22B
Sarepta Therapeutics focuses on RNA-targeted treatments, particularly for rare diseases, competing with Exicure's RNA-based therapeutic approaches.

About

Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Show more...
CEO
Mr. Jungsoo Kim
Employees
8
Country
United States
ISIN
US30205M3097

Listings

MU
DE
2H0.MU
STU
DE
2H0.STU
F
DE
2H0.F
XNAS
US
XCUR

0 Comments

Share your thoughts

FAQ

What is Exicure stock price today?▼
The current price of 2H0.MU is €5.02 EUR — it has increased by +152.9% in the past 24 hours. Watch Exicure stock price performance more closely on the chart.
What is Exicure stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Exicure stocks are traded under the ticker 2H0.MU.
When is the next Exicure earnings date?▼
Exicure is going to release the next earnings report on May 13, 2026.
What were Exicure earnings last quarter?▼
2H0.MU earnings for the last quarter are 19.62 EUR per share, whereas the estimation was -0.88 EUR resulting in a +2,331.58% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Exicure have?▼
As of April 14, 2026, the company has 8 employees.
In which sector is Exicure located?▼
Exicure operates in the Other sector.
When did Exicure complete a stock split?▼
Exicure has not had any recent stock splits.
Where is Exicure headquartered?▼
Exicure is headquartered in Redwood City, United States.